BioCentury
ARTICLE | Clinical News

Sacituzumab govitecan: Additional Phase I/II data

May 2, 2016 7:00 AM UTC

Interim data from 19 patients with relapsed or refractory metastatic urothelial cancer in the Phase II portion of an open-label, U.S. Phase I/II trial showed that 8, 10 and 12 mg/kg sacituzumab govite...